Medical Conditions - Primary Hyperoxaluria Type I

Lumasiran is indicated for treating primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients.

Nedosiran is an RNA-targeted therapy to reduce oxalate production by inhibiting hepatic lactate dehydrogenase, thus treating primary hyperoxaluria Type 1.

Primary hyperoxaluria type 1 (PH1) is a rare genetic disorder that leads to excessive oxalate production in the body. Read the below article.